[1] 黄海宁,张浩,汪海.沙利度胺抗肿瘤机制及其作用靶点CRBN的研究进展.中国药理学通报,2015,31:745-749.
[2] 吴国法,赵振华,张群伟,等.局部晚期乳腺癌给予多西他赛及阿霉素的临床效果研究.中国生化药物杂志,2017,37:401-403.
[3] 南月敏.肝硬化并发症诊治现状及展望.中华肝脏病杂志,2017,25:241-245.
[4] 王玮,刘海波.小剂量沙利度胺联合改良VCMP与VAD方案治疗老年多发性骨髓瘤的疗效比较.中国实验血液学杂志,2016,24:765-768.
[5] 张华,于静萍,倪新初,等.沙利度胺联合放疗治疗食管癌长期生存分析.中华放射医学与防护杂志,2015,35:437-440.
[6] 沈艳丽,姬晓南,高向东,等.抗甲胎蛋白单链抗体与阿霉素联合对人肝癌细胞 Huh7增殖的抑制作用.中国药科大学学报,2016,47:101-105.
[7] Kopanja D,Pandey A,Kiefer M,et al.Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features. J Hepatol,2015,63: 429-436.
[8] Hayashi T, Yamashita T, Terashima T, et al.Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.BMC Cancer,2017,17:870.
[9] Lu LH, Zhang YF, Wei W, et al.Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients.J Gastrointest Surg,2017,21:2025-2032. |
